Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Precision Treatment, Earlier Molecular Detection and De-escalation Transforming Breast Cancer Care
Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.
Breast cancer treatment is increasingly guided by molecular features and treatment response, alongside anatomic stage and conventional receptor classification.
2
Antibody-drug conjugates are moving into earlier disease settings and lines of therapy, including triple-negative and HER2-positive breast cancer.
3
In SERENA-6, blood detection of an emerging ESR1 mutation prompted an endocrine therapy change before radiographic progression and delayed disease progression.
4
De-escalation studies suggest selected patients may avoid regional lymph-node radiation, sentinel lymph-node surgery, or chemotherapy without compromising oncologic outcomes.
5
The role of ctDNA testing in early-stage disease remains uncertain because it is not yet established whether intervention on molecular recurrence improves outcomes.
